+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tuberculosis Drug"

Bedaquiline Sales Forecast and Market Size Analysis - 2034 - Product Thumbnail Image

Bedaquiline Sales Forecast and Market Size Analysis - 2034

  • Report
  • March 2026
  • 30 Pages
  • Global
From
From
Tuberculosis - Pipeline Insight, 2025 - Product Thumbnail Image

Tuberculosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Tuberculosis Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Tuberculosis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

The Tuberculosis Drug market is a subset of the larger Respiratory Drug market. It is composed of drugs used to treat tuberculosis, a bacterial infection that affects the lungs and other parts of the body. These drugs are typically antibiotics, such as isoniazid, rifampicin, and ethambutol, and are used in combination to treat the infection. The drugs are usually taken for a period of six to nine months, and are often used in combination with other treatments, such as surgery or chemotherapy. The Tuberculosis Drug market is highly competitive, with many companies offering different combinations of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Sanofi, Merck, and Novartis. Other companies, such as Cipla, Lupin, and Sun Pharmaceuticals, also offer a range of tuberculosis drugs. Show Less Read more